170 related articles for article (PubMed ID: 38637557)
1. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
Stefańczyk SA; Hagelstein I; Lutz MS; Müller S; Holzmayer SJ; Jarjour G; Zekri L; Heitmann JS; Salih HR; Märklin M
Blood Cancer J; 2024 Apr; 14(1):67. PubMed ID: 38637557
[TBL] [Abstract][Full Text] [Related]
2. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
[TBL] [Abstract][Full Text] [Related]
3. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
4. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
6. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
7. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
8. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody.
Schmied BJ; Lutz MS; Riegg F; Zekri L; Heitmann JS; Bühring HJ; Jung G; Salih HR
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817795
[TBL] [Abstract][Full Text] [Related]
9. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
[TBL] [Abstract][Full Text] [Related]
10. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.
Riegg F; Lutz MS; Schmied BJ; Heitmann JS; Queudeville M; Lang P; Jung G; Salih HR; Märklin M
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915811
[TBL] [Abstract][Full Text] [Related]
11. Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
Tyagi A; Ly S; El-Dana F; Yuan B; Jaggupilli A; Grimm S; Konopleva M; Bühring HJ; Battula VL
Blood; 2022 May; 139(18):2782-2796. PubMed ID: 35231101
[TBL] [Abstract][Full Text] [Related]
12. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
[TBL] [Abstract][Full Text] [Related]
15. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
16. An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity against Colorectal Cancer.
Schmied BJ; Riegg F; Zekri L; Grosse-Hovest L; Bühring HJ; Jung G; Salih HR
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181683
[TBL] [Abstract][Full Text] [Related]
17. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
18. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
20. Adaptive single-KIR
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikström K; Blomberg P; Alici E; Felices M; Önfelt B; Höglund P; Valamehr B; Ljunggren HG; Björklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg KJ; Sohlberg E
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
